Resonance Therapeutics (RTx) is an Australian medical technology company developing safe, effective, drug-free treatments for better mental health.   RTx is building a non-invasive neuromodulation system that can measure, analyse and stimulate the brain, providing uniquely personalised treatment for depression at-home.

Our team has been at the forefront of clinical brain stimulation research for over 20 years. Backed by research led by Professor Paul Fitzgerald and Professor Kate Hoy, having conducted numerous large clinical trials in device-based treatments in psychiatry and neuropsychology.

 

RTx spun out of Monash University in partnership with the neuromotion group, internationally established providers of high-performance neuroscience and clinical solutions, with 20 year track record of successfully bringing accredited software and medical grade devices to global markets.